Preclinical research has shown efficacy of combining mTOR inhibitors with PD‐1/PD‐L1 inhibitors in syngeneic mouse models of renal cell carcinoma [40] oral cavity cancer [41], and colorectal cancer [42]. The gene discussed is MTOR; the disease is renal cell carcinoma.